Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease
Top Cited Papers
- 17 January 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 113 (2) , 203-212
- https://doi.org/10.1161/circulationaha.105.505636
Abstract
Background— Studies have examined the use of evidence-based therapies for coronary artery disease (CAD) in the short term and at hospital discharge, but few have evaluated long-term use. Methods and Results— Using the Duke Databank for Cardiovascular Disease for the years 1995 to 2002, we determined the annual prevalence and consistency of self-reported use of aspirin, β-blockers, lipid-lowering agents, and their combinations in all CAD patients and of angiotensin-converting enzyme inhibitors (ACEIs) in those with and without heart failure. Logistic-regression models identified characteristics associated with consistent use (reported on ≥2 consecutive follow-up surveys and then through death, withdrawal, or study end), and Cox proportional-hazards models explored the association of consistent use with mortality. Use of all agents and combinations thereof increased yearly. In 2002, 83% reported aspirin use; 61%, β-blocker use; 63%, lipid-lowering therapy use; 54%, aspirin and β-blocker use; and 39%, use of all 3. Consistent use was as follows: For aspirin, 71%; β-blockers, 46%; lipid-lowering therapy, 44%; aspirin and β-blockers, 36%; and all 3, 21%. Among patients without heart failure, 39% reported ACEI use in 2002; consistent use was 20%. Among heart failure patients, ACEI use was 51% in 2002 and consistent use, 39%. Except for ACEIs among patients without heart failure, consistent use was associated with lower adjusted mortality: Aspirin hazard ratio (HR), 0.58 and 95% confidence interval (CI), 0.54 to 0.62; β-blockers, HR, 0.63 and 95% CI, 0.59 to 0.67; lipid-lowering therapy, HR, 0.52 and 95% CI, 0.42 to 0.65; all 3, HR, 0.67 and 95% CI, 0.59 to 0.77; aspirin and β-blockers, HR, 0.61 and 95% CI, 0.57 to 0.65; and ACEIs among heart failure patients, HR, 0.75 and 95% CI, 0.67 to 0.84. Conclusions— Use of evidence-based therapies for CAD has improved but remains suboptimal. Although improved discharge prescription of these agents is needed, considerable attention must also be focused on understanding and improving long-term adherence.Keywords
This publication has 20 references indexed in Scilit:
- The Concordance of Self-Report With Other Measures of Medication AdherenceMedical Care, 2004
- Comparability of quality-of-care indicators for emergency coronary angioplasty in patients with acute myocardial infarction regardless of on-site cardiac surgery (report from the National Registry of Myocardial Infarction)The American Journal of Cardiology, 2004
- Suboptimal statin adherence and discontinuation in primary and secondary prevention populationsJournal of General Internal Medicine, 2004
- Impact of Combination Evidence-Based Medical Therapy on Mortality in Patients With Acute Coronary SyndromesCirculation, 2004
- Health and Economic Benefits of Increased β-Blocker Use Following Myocardial InfarctionJAMA, 2000
- Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999Journal of the American College of Cardiology, 2000
- Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIbJournal of the American College of Cardiology, 1998
- Determinants of Appropriate Use of Angiotensin-Converting Enzyme Inhibitors After Acute Myocardial Infarction in Persons ≥65 Years of AgeThe American Journal of Cardiology, 1997
- Adverse Outcomes of Underuse of β-Blockers in Elderly Survivors of Acute Myocardial InfarctionJAMA, 1997
- Influence of Adherence to Treatment and Response of Cholesterol on Mortality in the Coronary Drug ProjectNew England Journal of Medicine, 1980